healthcare sector in india monthly update january 2013

7/29/2019 Healthcare Sector in India Monthly Update January 2013

http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-january-2013 1/14

Healthcare Sector in India

Monthly Update

January 2013



Healthcare – Monthly Update

Top Story

India meets WHO regulatory authority standard for vaccines

India has been praised by United Nations’ (UN) directing and coordinating authorityfor health, World Health Organization (WHO) for its healthcare efforts. India has been

appreciated for meeting the stringent WHO national regulatory assessment for

vaccines as well as for its role in lowering medicine prices and thereby ensuring

universal healthcare.

India’s effort in supplying vaccines to regions not funded by UN or any other

charitable organization led WHO in declaring that the country's national regulatory

authority and affiliated institutions meet the prescribed international standards to

supply vaccines to international bodies such as the WHO, UNICEF and the World

Bank.

News Update

General

Indus Health Plus enters into partnership with Apollo Hyderabad

Pune based preventive healthcare provider Indus Health Plus (P) Ltd. has extended its

operation in southern belt by entering into a partnership with Apollo Hospitals in

Hyderabad. The association marks Indus’ 55th centre through its tie up with 15 odd

hospitals. The firm was already in association with Ahmedabad located Apollo andafter its Hyderabad association, it has plans of setting up 30 more centers for lending

focus to southern and western India within the next year and a half.

Indus has been able to make a mark through its specially designed health packages for

different age groups. The firm has been able to tap Indians growing awareness of

early disease detection which has resulted in almost 25% increase in client base

annually.

GVK Biosciences signs pact with Onconova Therapeutics

Hyderabad based contract research organization (CRO) GVK Biosciences has entered

into an agreement with US‐based Onconova Therapeutics for development of newdrugs for treatment of cancer. As according to the deal, Onconova will provide two

discovery targets with early chemical equity while GVK Biosciences will use its multi‐

disciplinary discovery platform to advance these programmes through lead

optimization and investigational new drug (IND) candidate selection. The deal will

also see GVK Biosciences gain an increasing share of up to 50‐50 split based on

achievement of milestones or funding brought into the JV with advancement in their

target.




The proceedings in cancer development drugs will be based in US with the aim of

developing Onconova oncology assets from early discovery to clinical development

stage.

Biocon gains approval for Itolizumab

Bangalore based biotech firm Biocon has recently been awarded approval for its

treatment of skin disease psoriasis Itolizumab drug by the Drug Controller General of

India (DGCI). Following the approval from DGCI, the company is now in the process of

launching the product under the brand name Alzumab.

Indian pharma companies like Biocon and Glenmark who had ventured into research

almost a decade ago are gradually acquiring approvals that are throwing a positive

light on Indian drug manufacturing capability.

IIT-Madras

successful

in

generating

RBCs

from

stem

cells

A team of engineering department scientists of IIT Madras has been successful in

creating enough red blood cells (RBCs) from stem cells that could be used as artificial

blood who need transfusion. The team has also been approved a funding from the

Union Ministry of Science and Technology to produce artificial blood on an industrial

scale. The RBCs will soon go in for mass production before sending it for human trials

in 3 years span prior to being tested on animals.

If the trials prove to be successful, the perennial problem of blood shortage in

hospitals can be overcome that will save numerous accident victims. The blood

generated will have the added advantage of being disease free and will be available at

almost half the cost at which blood is now sold at.

Omron Healthcare launches convenient Blood Glucose Monitors

Medical technology provider Omron Healthcare India has launched much simplified

and economical “Blood Glucose Monitor – HGM111” and “Blood Glucose Monitor –

HGM112”. The products have been designed in a way that requires no coding and can

be operated with ease by diabetic patients sitting at home. The Blood Glucose Monitor

‐ HGM 111 provides accurate glucose measurement in 5 seconds and can store up to

512 sets of measurement with average data for 7, 14 and 30 days and can be

downloaded onto computer as well. Blood Glucose Monitor – HGM 112 too has

similar benefit of being light weight, easy to use and fast test results. Blood Glucose

Monitor – HGM111 is estimated at a price of INR 1,980 while Blood Glucose Monitor –HGM112 is estimated at a price of INR 990.

The surge in diabetic population over the years is drawing healthcare sector to greatly

focus on the particular segment. With launch of the products, Omron is looking

forward to improving the quality of an average Indian household’s preventive

healthcare standard.




News Update

Regulatory

Clinical trials

in

India

set

for

stricter

regulations

The Indian government has woken up to take charge of regulating the clinical trials

market seriously. The government is taking major initiatives in changing the drug

laws in order to do away with lapses made by MNC pharmaceutical majors a

punishable offense. The Health Ministry is in the process of introducing rules that

would monitor clinical trials under the Drugs and Cosmetics Act within Jan 2012.

Once the rules meant for the pharma companies conducting clinical trials on Indians

get notified, the government will further amend the Drugs and Cosmetics Act to make

lapses by pharma MNCs a punishable offence by law.

The Ministry will for the 1st time put specific responsibility on investigators and

sponsors of drug trials. This will make it mandatory for them to address issues of

medical management of subjects involved in trials in case of serious adverse

outcomes such as death. It will also prescribe a formula to provide for a higher

compensation in case of subject’s death and fix a minimum compensation for subjects

otherwise. Stricter norms in clinical trials are expected to make pharma companies

more careful in dealing with its subjects.

News Update

Expansion Plans

Aurobindo Pharma to launch migraine drug

Hyderabad based drug manufacturer Aurobindo Pharma Ltd. has acquired the final

approval for manufacturing and marketing of Rizatriptan Benzoate Tablets from US

Food and Drug Administration (USFDA). The product has been approved out of Unit

VII (SEZ) formulations facility in Hyderabad. The 5mg (base) and 10mg (base) dose is

indicated for acute treatment of migraine with or without aura in adults and in

pediatric patients between 6 to 17 years of age.

The medication is a generic equivalent of Merck and Co's Maxalt Tablets. With generic

equivalents getting approvals there is a growing accessibility to cheaper alternatives.

Moolchand acquires Pankaj Apollo Hospital

Moolchand Healthcare has recently announced its acquisition of Agra based Pankaj

Apollo Hospital. Moolchand has plans of expanding the 200‐bedded tertiary care

hospital to a 300‐bed facility with a total investment of INR 0.75 bn. This acquisition is

in line with Moolchand’s INR 5 bn expansion plan that it had envisaged in early 2012.

The group has plans of expanding the hospital with a comprehensive cancer institute




within the next 18 months, while in second phase the hospital will be expanded to

300 beds. This acquisition has enabled Moolchand expand its presence to western UP

that otherwise has few leading hospital groups operating.

Indian pharma majors to supply life saving drugs to Iran

Indian dug manufacturers Ranbaxy, Cipla, Glenmark and Ind‐Swift Laboratories have

been roped in to supply life saving drugs to the Islamic Republic of Iran. The decision

came after representatives of Glenmark, Ind‐Swift and Hetero Drugs were invited to

Tehran to the meeting led by Pharmaceuticals Export Promotion Council of India

(Pharmexcil) during Dec 17th to Dec 19th, 2012. The Government of Iran has

requested supply of bulk drugs, active pharmaceutical ingredients (APIs) and generic

formulations for treatment of lung and breast cancers, brain tumours, heart ailments

and other key diseases.

The payment by Iran will be made in Indian rupee, however both countries’government have agreed that the companies supplying drugs will enjoy benefits of

dollar payment mode. USA being a big importer of Indian generic pharmaceuticals,

India should carefully expand its export business by fulfilling Iran’s requirements.

ICT Health expands India business

Bangalore based ICT Health Technology Services has installed its Health Information

and Management System HINAI hospital enterprise solution at Narayana Hrudayalaya

(NH) Group Hospitals. The single, multi‐tenant, cloud has connected 17 hospitals

under NH Group.

ICT Healthcare already has a strong market base in Middle East and is trying toexpand its market in India. The company already provides cloud assistance to over 25

hospitals and diagnostic centers by integrating data of more than a million patients

world over, is now targeting to integrate 3 mn patient population data by 2013 and

raise the statistic to 5 mn by 2014.

Stemade launches dental stem cell banking facility

Mumbai based Stemade Biotech Pvt. Ltd. has drawn a partnership with Ludhiana

based Dr Vivek Saggar's Dental Care and Cure Centre and Dr Vikas Jindal's Jindal

Smile Clinic for providing dental stem cell banking service by launching Stemade

Connect Clinics (SCC).

Stemade is making efforts in penetrating beyond the metro cities that will enable

biological insurance to customers even in lesser developed tier II and tier III towns

and cities.




Industry Expert Speak

Indus Health Plus enters into partnership with Apollo Hyderabad - Amol

Naikawadi, Joint

Managing

Director,

Indus

Health

“We already have a tie‐up with Apollo Group in Ahmadabad. We now decided to

extend the association to Hyderabad. We now plan to add 30 more centers, a majority

in the southern and western States, in the next 12 to 18 months. We will also be tying

up with new hospitals as we expand our network.”

Biocon gains approval for Itolizumab - Kiran Mazumdar Shaw, Managing

Director, Biocon

"This approval paves the way for us to extend clinical development for other

indications like rheumatoid arthritis, multiple sclerosis and vitiligo. We also intend to

file a US IND (Investigational New Drug) shortly to enable us to embark on a global

clinical development plan"

IIT-Madras successful in generating RBCs from stem cells - Dr Soma

Guhathakurta, Visiting Professor at Department of Engineering Design IIT -M

"Almost all earlier attempts have had at least 40% of white blood cells in the culture.

Introducing such artificial blood into a patient with a weak immune system could be

tricky. As a surgeon, I would prefer only red blood cells,"

Transactions (Nov 2012 – Jan 2013)

Date Buyer Target Deal Size

(INR mn) % stake Deal Status

Type of

Transaction

23rd Jan

2013Tata Capital

Marck

Biosciences Ltd.450 13% Completed Private Equity

18th Jan

2013

Sequoia Capital

India

ASG Eye

Hospitals500 N.A. Completed Private Equity




17th Jan

2013

Norwest

Venture

Partners

Nueclear

Healthcare220 N.A. Completed Private Equity

7th Jan2013

Lok CapitalDrishti Eye Care

Pvt. Ltd.N.A. N.A. Completed Private Equity

4th Jan

2013

Artiman

Ventures

Core Diagnostics

Pvt. Ltd. 270 N.A. Completed Private Equity

3rd Jan

2013

Ashmore

Alchemy IndiaAdvisors

Zim Laboratories

Ltd.450 N.A. Completed Private Equity

2nd Jan2013

MoolchandHealthcare Ltd.

Pankaj ApolloHospital

N.A. N.A. Completed M&A

20th Dec

2012

Transasia Bio‐

Medicals Ltd.

Drew Scientific

Inc.and

JAS Diagnostics

Inc.

N.A. N.A. N.A. Completed

17th Dec2012

Bupa AustraliaHealth Pty Ltd.

Fortis Healthcare

Ltd. heldAustralia’s

DentalCorporation

Holdings Ltd

11276 64% Planned M&A




17th Dec

2012

CaracoPharmaceutical

Laboratories(Wholly owned

subsidiary of Sun

Pharmaceutical

Industries)

URL Pharma(Owned by

Japanese

drugmakerTakeda

Pharmaceuticals)

N.A. N.A. Planned M&A

15th Dec

2012

ErbaDiagnostics

US arm of

TransasiaBio‐Medicals

Ltd.

Drew ScientificInc and JAS

Diagnostics Inc,

fromEscalon Medical

Corp


11th Dec

2012

Sutherland

Global Services

Apollo HealthStreet

(AHS)

10000 100% Planned M&A

4th Dec2012

Decision

ResourcesGroup (DRG)Subsidiary of

PiramalEnterprises

AbacusInternational


4th Dec2012

Matrix PartnersIndia

EnhanceAesthetic and

Cosmetic StudioPvt. Ltd.


26th Nov

2012

Trivitron

Healthcare Pvt.Ltd.

Ani Labsystems

Ltd.1221.12 N.A. Completed M&A

22nd Nov2012

IncuCapitalNavigene GeneticScience Pvt. Ltd.

N.A. N.A. Completed Private Equity

21st Nov2012

Cipla Ltd.Cipla Medpro

South Africa Ltd.12101.2 51% Completed M&A

8th Nov2012

Sun PharmaIndustries Ltd.

DUSAPharmaceuticals,

Inc.

12.65 N.A. Planned M&A




Annual Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies FY ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0

Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5

Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7

Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0

Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0

Dr. Reddy’s Laboratories

(DRL)69,441.00 70,277.00 74,693.00 96,737.4

GlaxosmithKlineConsumer Healthcare

Ltd.19,757.6 23,693.3 27,688.6 28,857.3

Glenmark Pharmaceuticals Ltd.

21,241.20 25,291.30 29,490.70 40,206.4

Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5

Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1

Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0

Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543

Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3

Ranbaxy LaboratoriesLtd.

75,970.40 89,607.70 101,614.1 117,153.2

Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9

Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1

Sun PharmaceuticalsIndustries Ltd.

42,723.00 38,086.30 57,214.30 80,056.6

Torrent Pharmaceuticals

Ltd.16,306.60 19,160.40 22,264.80 26,959.2

Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0




Annual Financial Results – Income (INR mn) -Major Healthcare

Companies

Companies FY ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0

Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0


Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4

Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0


(DRL)‐5,168.00 1,068.00 11,040.00 14,262.1

GlaxoSmithKline ConsumerHealthcare Ltd.

2,327.8 2,998.5 3,552.1 3,765.6

Glenmark Pharmaceuticals

Ltd.1,916.60 3,244.70 4,532.10 4,603.5

Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6

Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5

Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7


Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0

Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5

Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6

Strides Arcolab Ltd. 1,096.80 1,224.50 2,244.8 8,258.4




Sun PharmaceuticalsIndustries Ltd.

18,177.30 13,510.80 18,160.60 25,872.5

Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4

Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1

Quarterly Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies Oct

-Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Jul-Sep

2012

Biocon Ltd. 5,171.90 5,892.2 5,770.0 5,924.0

Blue Star Ltd. 5,896.9 N.A. N.A. N.A.


Cipla Ltd. 17,580.00 N.A N.A. N.A.

Dabur India Ltd. 14,526.80 13,858.3 14,620.0 15,226.0


(DRL)27,692.00 26,584.0 25,406.0 28,808.5

GlaxoSmithKline ConsumerHealthcare Ltd.

6,854.0 8,608.7 7,869.6 8,275.4

Glenmark PharmaceuticalsLtd.

10,310.90 10,751.2 10,404.1 12,551.9

Jubilant life Sciences Ltd. 10,871.70 12,235.9 12,358.9 12,197.3

Lupin Ltd. 17,917.0 20,063.7 22,191.5 22,392.6

Nestle India Ltd. 19,633.2 20,558.7 19,865.8 21,155.9


Piramal Enterprises Ltd. 5,518.30 8,858.0 7,102.9 8,285.8

Ranbaxy Laboratories Ltd. 37,923.1 36,954.0 31,740.6 26,513.9




Ranbaxy Laboratories Ltd. ‐29,827.7 12,467.6 ‐5,857.3 7,541.7

Siemens India Ltd. 1,873.6 3,040.0 (157.8) (557.7)

Strides Arcolab Ltd 684.1 6,420.7 904.8 524.9

Sun Pharmaceuticals

Industries Ltd.6,683.0 8202.1 7,955.5 3,196.4

Torrent Pharmaceuticals Ltd 831.8 ‐16.5 1,018.5 1,072.5

Wockhardt Ltd. 2,128.10 ‐1,916.4 3,779.7 4,535.5

Events Calendar

Health 2.0 Everywhere! – Health 2.0 India

Date:

8th

– 9th

Feb, 2013Venue: CMR Institute of Technology, BengaluruContact No: +91 80 2852 4466

Website :

www.health2con.com/events/conferences/indi

a‐2013/

India Bio 2013

Date: 4th – 6th, 2013Venue: The Lalit Ashok, Bengaluru

Contact No: +91 080 4113 1912 / 13

Website: www.bangaloreindiabio.in

Medicall 2013

Date: 8th – 10th Feb, 2013Venue: Gujarat University Exhibition Hall,

Ahmedabad

Website: medicall.in/medicall/ahamedbad‐

venue.php




Research on India (ROI) is a leading source for market research on various sectors in

India that offers premium research content from worldwide publishers of market

research reports.

Contact us:

W: https://www.researchonindia.com

T: India (Toll Free): 1800 102 1133; International: +91 (33) 4027 6214/5

E: [email protected]

Connect with Us

Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.

http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

https://twitter.com/ResearchOnIndia

http://www.facebook.com/researchonindia

healthcare sector in india monthly update january 2013

Documents